Development of gastric cancer and its prevention

Archives of Iranian Medicine

Volumn 17, Issue 7, 2014, Pages 514-520

  Massarrat, Sadegh ^a   Stolte, Manfred ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Klinikum Kulmbach   (Germany)

Author keywords

Gastric cancer; Pathogenesis; Pepsinogen II; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; INTERLEUKIN 1; INTERLEUKIN 1BETA; NONSTEROID ANTIINFLAMMATORY AGENT; PEPSINOGEN I; PEPSINOGEN II; UVOMORULIN; BIOLOGICAL MARKER;

ACHLORHYDRIA; ALCOHOL CONSUMPTION; ATROPHIC GASTRITIS; ATROPHY; BLOOD GROUP A; CANCER PREVENTION; CHEMOPROPHYLAXIS; ENDOSCOPY; ENZYME BLOOD LEVEL; GASTRECTOMY; HELICOBACTER INFECTION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HEREDITY; HUMAN; INTESTINE METAPLASIA; META ANALYSIS (TOPIC); MONONUCLEAR CELL; MUCOSA INFLAMMATION; NEOPLASM; NEUTROPHIL CHEMOTAXIS; PEUTZ JEGHERS SYNDROME; REVIEW; SALT INTAKE; SMOKING HABIT; SOCIAL STATUS; STOMACH ANTRUM; STOMACH CANCER; BLOOD; CARCINOMA; COMPLICATION; DIET; DISEASE COURSE; DRINKING BEHAVIOR; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; METAPLASIA; PATHOLOGY; SMOKING; STOMACH; STOMACH NEOPLASMS;

ALCOHOL DRINKING; BIOLOGICAL MARKERS; CARCINOMA; DIET; DISEASE PROGRESSION; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METAPLASIA; PEPSINOGEN C; SMOKING; STOMACH; STOMACH NEOPLASMS;

EID: 84904213394     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. WorldJ Gastroenterol. 2006; 12: 354-362.
2. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer. 1990; 62: 440-443.
3. Kuipers EJ. Review article: exploring the link between Helicobacter pylori and gastric cancer. Aliment Pharmacol Ther. 1999; 13 (Suppl 1): 3-11.
4. Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004; 128: 765-770.
5. Banatvala N, Mayo K, Meg raud F, Jennings R, Deeks JJ, Feldman RA. The cohort effect and Helicobacter pylori. J Infect Dis. 1993; 168: 219-221.
6. Akoh JA, Macintyre IM. Improving survival in gastric cancer: review of 5-year survival rates in English. Br J Surg. 1992; 79: 293-299.
7. Valle J, Kekki M, Sipponen P, Ihamaki T, Siurala M. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol. 1996; 31: 546-550.
8. Haj-Sheykholeslami A, Rakhshani N, Amirzargar A, Rafiee R, Sha- hidi SM, Nikbin B, et al. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol. 2008; 6: 174-179.
9. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992; 52: 6735-6740.
10. Meining A, Bayerdorfer E, Muller P, Miehlke S, Lehn N, Holzel D, et al. Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch. 1998; 432: 311-314.
11. Seevaratnam R, Coburn N, Cardoso R, Dixon M, Bocicariu A, He- lyer L. A systematic review of the indications for genetic testing and prophylactic gastrectomy among patients with hereditary diffuse gastric cancer. Gastric Cancer. 2012; 15 (Suppl 1): S153-S163.
12. Xue H, Lin B, Ni P, Xu H, Huang G. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol. 2010; 25: 1604-1617.
13. Kamangar F, Cheng C, Abnet CC, Rabkin CS. Interleukin-1B polymorphisms and gastric cancer risk--a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1920-1928.
14. van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Stey- erberg EW, van Leerdam ME. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010; 105: 1258-1264.
15. Capelle LG, Van Grieken NC, Lingsma HF, Steyerberg EW, Klok- man WJ, Bruno MJ, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology. 2010; 138: 487-492.
16. Edgren G, Hjalgrim H, Rostgaard K, Norda R, Wikman A, Mel- bye M, et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol. 2010; 172: 1280-1285.
17. Nakao M, Matsuo K, Ito H, Shitara K, Hosono S, Watanabe M, et al. ABO genotype and the risk of gastric cancer, atrophic gastritis, and Helicobacter. Cancer Epidemiol Biomarkers Prev. 2011; 20: 1665-1672.
18. Kuwahara A, Takachi R, Tsubono Y, Sasazuki S, Inoue M, Tsugane S, JPHC Study Group. Socioeconomic status and gastric cancer survival in Japan. Gastric Cancer. 2010; 13: 222-230.
19. Uthman OA, Jadidi E, Moradi T. Socioeconomic position and incidence of gastric cancer: a systematic review and meta-analysis. Eur J Cancer. 1998; 34: 537-542.
20. Aguilar I, Compés L, Feja C, Rabanaque MJ, Martos C. Gastric cancer incidence and geographical variations: the influence of gender and rural and socioeconomic factors, Zaragoza (Spain). Gastric Cancer. 2013; 16: 245-253.
21. Graham DY, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology. 1991; 100: 1495-1501.
22. Barbeau EM, Krieger N, Soobader MJ. Working class matters: socioeconomic disadvantage, race/ethnicity, gender, and smoking in NHIS 2000. Am J Public Health. 2004; 94: 269-278.
23. Irala-Estévez JD, Groth M, Johansson L, Oltersdorf U, Prattala R, Martínez-González MA. A systematic review of socio-economic differences in food habits in Europe: consumption of fruit and vegetables. Eur J Clin Nutr. 2000; 54: 706-714.
24. Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991; 302: 1302-1305.
25. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. New England J Med. 1991; 325: 1127-1131.
26. Epplein M, Zheng W, Xiang YB, Peek RM Jr, Li H, Correa P, et al. Prospective study of Helicobacter pylori biomarkers for gastric cancer risk among Chinese men. Cancer Epidemiol Biomarkers Prev. 2012; 21: 2185-2192.
27. Suzuki G, Cullings H, Fujiwara S, Hattori N, Matsuura S, Hakoda M, et al. Low-positive antibody titer against Helicobacter pylori cy- totoxin. Cancer Epidemiol Biomarkers Prev. 2012; 21: 2185.
28. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Metaanalysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2003; 125: 1636-1644.
29. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. New Engl J Med. 2001; 345: 784-789.
30. Masci E, Viale E, Freschi M, Porcellati M, Tittobello A. Precance- rous gastric lesions and Helicobacter pylori. Hepatogastroenterol- ogy. 1996; 43: 854-858.
31. Kikuchi S. Epidemiology of Helicobacter pylori and gastric cancer. Gastric Cancer. 2002; 5: 6-15.
32. Suzuki G, Cullings H, Fujiwara S, Hattori N, Matsuura S, Hakoda M, et al. Low-positive antibody titer against Helicobacter pylori cy- totoxin-associated gene A (CagA) may predict future gastric cancer better than simple seropositivity against H. pylori CagA or against H. pylori. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1224-1228.
33. Ladeiras-Lopes R, Pereira AK, Nogueira A, Pinheiro-Torres T, Pinto I, Santos-Pereira R, et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control. 2008; 19: 689-701.
34. Shikata K, Doi Y, Yonemoto K, Arima H, Ninomiya T, Kubo M, et al. Population-based prospective study of the combined influence of cigarette smoking and Helicobacter. Am JEpidemiol. 2008; 168: 1409-1415.
35. Hoey J, Montvernay C, Lambert R. Wine and tobacco: risk factors for gastric cancer in France. Am J Epidemiol. 1981; 113: 668-674.
36. Moy KA, Fan Y, Wang R, Gao YT, Yu MC, Yuan JM. Alcohol and tobacco use in relation to gastric cancer: a prospective study of men in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2010; 19: 2287-2297.
37. Everatt R, Tamosiunas A, Kuzmickiene I, Virviciute D, Radisaus- kas R, Reklaitiene R, et al. Alcohol consumption and risk of gastric cancer: a cohort study of men in Kaunas, Lithuania, with up to 30 years follow-up. BmC Cancer. 2012; 12: 475.
38. Duell EJ, Travier N, Lujan-Barroso L, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, et al. Alcohol consumption and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Am J Clin Nutr. 2011; 94: 1266-1275.
39. Sung NY, Choi KS, Park EC, Park K, Lee SY, Lee AK, et al. Smoking, alcohol and gastric cancer risk in Korean men: the National Health Insurance Corporation Study. Br J Cancer. 2007; 97: 700-704.
40. Tramacere I, Negri E, Pelucchi C, Bagnardi V, Rota M, Scotti L, et al. A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol. 2012; 23: 28-36.
41. Shimazu T, Tsuji I, Inoue M, Wakai K, Nagata C, Mizoue T, et al. Alcohol drinking and gastric cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Jpn J ClinOncol. 2008; 38: 8-25.
42. Joossen Jv, Hill MJ, Elliott P, Stamler R, Stamler J, Lesaesaf- free E, et al. Intersalt cooperative research group. Gastroenterol Res Pract. 2012; 2012: 808120.
43. Ge S, Feng X, Shen L, Wei Z, Zhu Q, Sun J. Association between habitual dietary salt intake and risk of gastric cancer: A systematic review of oservational studies. Gastroenterol Res Pract. 2012; 2012: 808120.
44. D'Elia L, Rossi G, Ippolito R, Cappuccio FP, Strazzullo P. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr. 2012; 31: 489-498.
45. Peleteiro B, Lopes C, Figueiredo C, Lunet N. Salt intake and gastric cancer risk according to Helicobacter pylori infection, smoking, tumour site and histological type. Br J Cancer. 2011; 104: 198-207.
46. Kim J, Park S, Nam BH. Gastric cancer and salt preference: a population-based cohort study in Korea. Am J Clin Nutr. 2010; 91: 1289-1293.
47. Shikata K, Kiyohara Y, Kubo M, Yonemoto K, Ninomiya T, Shirota T, et al. A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama study. Int J Cancer. 2006; 119: 196-201.
48. Bertuccio P, Rosato V, Andreano A, Ferraroni M, Decarli A, Edefonti V, et al. Dietary patterns and gastric cancer risk: a systematic review and meta-analysis. Ann Oncol. 2013; 24: 1450-1458.
49. Park B, Shin A, Park SK, Ko KP, Ma SH, Lee EH, et al. Ecological study for refrigerator use, salt, vegetable, and fruit intakes, and gastric cancer. Cancer Causes Control. 2011; 22: 1497-1502.
50. Bonequi P, Meneses-González F, Correa P, Rabkin CS, Camargo MC. Risk factors for gastric cancer in Latin America: a meta-analysis. Cancer Causes Control. 2013; 24: 217-231.
51. Bertuccio P, Edefonti V, Bravi F, Ferraroni M, Pelucchi C, Negri E, et al. Nutrient dietary patterns and gastric cancer risk in Italy. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2882-2886.
52. Jenab M, Riboli E, Ferrari P, Friesen M, Sabate J, Norat T, et al. Plasma and dietary carotenoid, retinol and tocopherol levels and the risk of gastric adenocarcinomas in the European prospective investigation into cancer and nutrition. Br J Cancer. 2006; 95: 406-415
53. Zhang Z, Xu G, Ma M, Yang J, Liu X. Dietary fiber intake reduces risk for gastric cancer: a meta-analysis. Gastroenterology. 2013; 145: 113-120.
54. Roosendaal R, Kuipers EJ, Buitenwerf J, van Uffelen C, Meuwis- sen SG, van Kamp GJ, et al. Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol. 1997; 92: 1480-1482.
55. Carneiro E. Hereditary gastric cancer. Der Pathologe. 2012; 33 (Suppl 2): 231-234.
56. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2003 3; 95: 1784-1791.
57. Yun Dai, Wei-Hong Wangy. Non-steroidal anti-inflammatory drugs in articles. World J Gastroenterol. 2006; 12: 2884-2889.
58. Wang J, Xu L, Shi R, Huang X, Li SW, Huang Z, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion. 2011; 83: 253-260.
59. Massarrat S, Haj-Sheykholeslami A, Mohamadkhani A, Zendehdel N, Rakhshani N, Stolte M, et al. Precancerous conditions after H. pylori eradication; a randomized double blind study in first degree relatives of gastric cancer patients. Arch Iran Med. 2012; 15: 664-669.
60. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2006; 372: 392-397.
61. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009; 151: 121-128.
62. Chow WH, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 1998; 58: 588-590.
63. Labenz J, Blum AL, Bayerdorfer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997; 112: 1442-1447.
64. Fallone CA, Barkun AN, Friedman G, Mayrand S, Loo V, Beech R, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol. 2000; 95: 914-920.
65. Miki K, Ichinose M, Kakei N, Yahagi N, Matsushima M, Tsukada S, et al. The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer. Adv Exp Med Biol. 1995; 362: 139-143.
66. Miwa H, Ghoshal UC, Gonlachanvit S, Gwee KA, Ang TL, Chang FY, et al. Asian consensus report on functional dyspepsia. J Neuro- gastroenterolMotil. 2012; 18: 150-168.
67. Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JIN, Yuan Y. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology. 1982; 83: 204-209.
68. Kiyohira K, Yoshihara M, Ito M, Haruma K, Tanaka S, Chayama K. Serum pepsinogen concentration as a marker of Helicobacter pylori infection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels. J Gastroenterol. 2003; 38: 332-338.
69. He CY, Sun LP, Gong YH, Xu Q, Dong N. Serum pepsinogen II: a neglected but useful biomarker to differentiate between diseased and normal stomachs. J Gastroenterol Hepatol. 2011; 26: 1039-1046.
70. Hunter FM, Correa P, Fontham E, Ruiz B, Sobhan M, Samloff IM. Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis. Dig Dis Sci. 1993; 38: 2081-2086.
71. Hackelsberger, Gunther T, Schultze V, Peitz U, Malfertheiner P Role of Aging in the Expression of Helicobacter pylori Gastritis in the Antrum, Corpus, and Cardia. Scand J gastroenterol. 1999; 34: 138-143.
72. Sipponen P, Stolte M. Clinical impact of routine biopsies of the gastric antrum and body. Endoscopy. 1997; 29: 671-678.